While there are a host of different skills that make human beings the most dominant species on the block, there aren’t many more significant than our ability to grow on a rather consistent basis. You see, when a person is able to grow under all possible situations, they make themselves eligible for some notable milestones along the way. This has been substantiated by all what we have achieved so far, and one such representation of the same happens to be a creation called technology. To be fair, technology was actually a unique case from the get-go because it gave us an identity which was dramatically smarter than everything we had seen till that point. The stated reality, of course, would go on to scale up our entire spectrum, including a highly-critical sector of healthcare. In fact, technology’s foray into healthcare couldn’t have come at a better time, considering it happened right when the sector was struggling against an outright obsolete structure. Nevertheless, even after giving the sector a fresh lease of life, this famous medtech linkup will continue to deliver all the right goods, and one recent funding does a lot to further the said pattern.
Gemelli Biotech, a company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, has officially raised over $19 million in Series A financing. Led by Blue Ox Healthcare Partners, Cedars-Sinai, the round saw further participation coming from the likes of Carolina Angel Network, CerraCap Ventures, and many other investors. According to certain reports, Gemelli will use the newly-raised cash to accelerate the commercialization of its new trio-smart and ibs-smart precision diagnostic tests. Beyond that, the company plans on dedicating a sizeable chunk of the funds towards the expansion of its manufacturing and laboratory facilities across US, while also bolstering its overall marketing efforts.
Since starting out in 2018, Gemelli has made some huge strides in regards to improving the landscape of precision diagnostics for GI diseases. The company has done so by treating microbiome-related biological discoveries as the ultimate centerpiece. This approach has allowed Gemelli to deliver non-invasive precision diagnostics that, in turn, will go on to help clinicians with detecting scientifically-validated biomarkers and optimally treating GI diseases including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS.
“Our innovative, non-invasive diagnostic technologies advance the level of actionable, scientifically validated biomarker and analytic information that enables clinicians to more definitively detect and optimize treatment of patients with gastrointestinal diseases,” said Matt Mitcho, co-founder and CEO of Gemelli Biotech. “This funding – combined with the involvement and insights of this well-regarded group of investors – will enable us to accelerate our business and bring our leading diagnostic testing products to more people.”
Talk about the company’s latest solutions, trio-smart is the only clinical breath test that measures levels of hydrogen, methane, and hydrogen sulfide to provide clinicians with a comprehensive picture of the patient’s gut health. On the other hand, ibs-smart is a patented diagnostic blood test for post-infectious irritable bowel syndrome (IBS). Interestingly, both products were developed in partnership with the Medically Associated Science and Technology program at Cedars-Sinai.
